About CHIGENOVO
CHIGENOVO is a company based in China founded in 2016. CHIGENOVO has raised $26.45 million across 3 funding rounds from investors including Kunlun Capital, Gimpo Investment and Yingke Capital. CHIGENOVO offers products and services including Gene Therapy Drugs and Gene Diagnosis Services.
- Headquarter Changping District, China
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name 北京中因科技有限公司
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$26.45 M (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
Kunlun Capital
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CHIGENOVO
CHIGENOVO offers a comprehensive portfolio of products and services, including Gene Therapy Drugs and Gene Diagnosis Services.
Gene therapy drugs for hereditary eye diseases are developed and evaluated.
Precise genetic diagnosis for eye diseases is offered through sequencing and analysis.
Funding Insights of CHIGENOVO
CHIGENOVO has successfully raised a total of $26.45M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(23 Mar 2021)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series A - CHIGENOVO | Valuation | Kunlun Capital | |
| Mar, 2022 | Amount | Series A - CHIGENOVO | Valuation |
investors |
|
| Mar, 2021 | Amount | Seed - CHIGENOVO | Valuation | Longmen Capital , Lotus Lake Capital Management |
|
Investors in CHIGENOVO
CHIGENOVO has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Kunlun Capital, Gimpo Investment and Yingke Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in technology companies are managed by Kunlun Capital.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by CHIGENOVO
Financial Statements - CHIGENOVO
Chigenovo Comparisons
Competitors of CHIGENOVO
Latest news on Chigenovo
Frequently Asked Questions about CHIGENOVO
CHIGENOVO was founded in 2016 and raised its 1st funding round 5 years after it was founded.
CHIGENOVO is headquartered in China. It is registered at Beijing, China.
CHIGENOVO is a funded company, having raised a total of $26.45M across 3 funding rounds to date. The company's 1st funding round was a Seed of $10.75M, raised on Mar 23, 2021.
CHIGENOVO was founded in 2016 and is located in Changping District, China. Operations are centered in the biotechnology sector, where gene therapy drugs for inherited eye diseases are developed alongside genetic diagnosis services. Focus is placed on high-tech advancements to address these conditions through innovative therapeutic and diagnostic approaches. The company operates as a specialized enterprise in this niche.
CHIGENOVO offers Gene Therapy Drugs and Gene Diagnosis Services.
CHIGENOVO has 7 investors. Key investors include Kunlun Capital, Gimpo Investment, Yingke Capital, Huayi Capital, and Junci Investment.